185 related articles for article (PubMed ID: 23597562)
1. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties.
Bono F; De Smet F; Herbert C; De Bock K; Georgiadou M; Fons P; Tjwa M; Alcouffe C; Ny A; Bianciotto M; Jonckx B; Murakami M; Lanahan AA; Michielsen C; Sibrac D; Dol-Gleizes F; Mazzone M; Zacchigna S; Herault JP; Fischer C; Rigon P; Ruiz de Almodovar C; Claes F; Blanc I; Poesen K; Zhang J; Segura I; Gueguen G; Bordes MF; Lambrechts D; Broussy R; van de Wouwer M; Michaux C; Shimada T; Jean I; Blacher S; Noel A; Motte P; Rom E; Rakic JM; Katsuma S; Schaeffer P; Yayon A; Van Schepdael A; Schwalbe H; Gervasio FL; Carmeliet G; Rozensky J; Dewerchin M; Simons M; Christopoulos A; Herbert JM; Carmeliet P
Cancer Cell; 2013 Apr; 23(4):477-88. PubMed ID: 23597562
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling.
Herbert C; Schieborr U; Saxena K; Juraszek J; De Smet F; Alcouffe C; Bianciotto M; Saladino G; Sibrac D; Kudlinzki D; Sreeramulu S; Brown A; Rigon P; Herault JP; Lassalle G; Blundell TL; Rousseau F; Gils A; Schymkowitz J; Tompa P; Herbert JM; Carmeliet P; Gervasio FL; Schwalbe H; Bono F
Cancer Cell; 2013 Apr; 23(4):489-501. PubMed ID: 23597563
[TBL] [Abstract][Full Text] [Related]
3. [SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling].
Herbert C; Alcouffe C; Bono F
Med Sci (Paris); 2013 Oct; 29(10):834-6. PubMed ID: 24148118
[No Abstract] [Full Text] [Related]
4. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
5. The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases.
Lee JS; Kang Y; Kim JT; Thapa D; Lee ES; Kim JA
Eur J Pharmacol; 2012 Feb; 677(1-3):22-30. PubMed ID: 22200628
[TBL] [Abstract][Full Text] [Related]
6. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
8. Tumor vasculature is regulated by FGF/FGFR signaling-mediated angiogenesis and bone marrow-derived cell recruitment: this mechanism is inhibited by SSR128129E, the first allosteric antagonist of FGFRs.
Fons P; Gueguen-Dorbes G; Herault JP; Geronimi F; Tuyaret J; Frédérique D; Schaeffer P; Volle-Challier C; Herbert JM; Bono F
J Cell Physiol; 2015 Jan; 230(1):43-51. PubMed ID: 24760775
[TBL] [Abstract][Full Text] [Related]
9. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
10. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.
Ezzat S; Huang P; Dackiw A; Asa SL
Clin Cancer Res; 2005 Feb; 11(3):1336-41. PubMed ID: 15709206
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms.
Auguste P; Gürsel DB; Lemière S; Reimers D; Cuevas P; Carceller F; Di Santo JP; Bikfalvi A
Cancer Res; 2001 Feb; 61(4):1717-26. PubMed ID: 11245488
[TBL] [Abstract][Full Text] [Related]
13. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
14. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
Bello E; Colella G; Scarlato V; Oliva P; Berndt A; Valbusa G; Serra SC; D'Incalci M; Cavalletti E; Giavazzi R; Damia G; Camboni G
Cancer Res; 2011 Feb; 71(4):1396-405. PubMed ID: 21212416
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer.
Brooks AN; Kilgour E; Smith PD
Clin Cancer Res; 2012 Apr; 18(7):1855-62. PubMed ID: 22388515
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
17. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
18. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
19. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
